Overview

Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

A Phase I, Open-Label, Randomized, Crossover Trial to Investigate the Relative Bioavailability of the 25 mg Dapivirine Vaginal Ring-004 inserted every 30 days and 100 mg Dapivirine Vaginal Ring-008 inserted for 90 days in Healthy Female Participants

Phase:

Phase 1

Details

Lead Sponsor:

International Partnership for Microbicides, Inc.

Treatments:

Dapivirine